Incidence and characteristics of chronic and lymphoplasmacytic sclerosing pancreatitis in patients scheduled to undergo a pancreatoduodenectomy  by De Castro, Steve M.M. et al.
ORIGINAL ARTICLE
Incidence and characteristics of chronic and lymphoplasmacytic
sclerosing pancreatitis in patients scheduled to undergo a
pancreatoduodenectomyhpb_112 15..21
Steve M.M. de Castro1, Lindsey C.F. de Nes1, C. Yung Nio2, Daan C. Velseboer3, Fiebo J.W. Ten Kate3,
Olivier R.C. Busch1, Thomas M. van Gulik1 & Dirk Jan Gouma1
Departments of 1Surgery, 2Radiology, and 3Pathology, Academic Medical Center, Amsterdam, the Netherlands
Abstract
Background: The determination of the exact nature of a pancreatic head mass in a patient scheduled
to undergo a pancreatoduodenectomy can be very difficult. This is important as patients who suffer from
benign disease such as pancreatitis do not always require surgery. The aim of the present study was to
analyse the incidence of pancreatitis and the signs and symptoms associated with these tumours
mistaken for pancreatic cancer and the diagnostic procedures performed.
Methods: A consecutive group of patients who underwent a pancreatoduodenectomy between 1992
and 2005 with histopathologically proven pancreatic adenocarcinoma (PCA) and pancreatitis were
analysed.
Results: The incidence of pancreatitis after pancreatoduodenectomy is 63 out of 639 patients who
underwent a pancreaticoduodenectomy (9.9%). Of these patients, 24 patients (38%) had lymphoplas-
macytic sclerosing pancreatitis (LPSP) and 31 patients (49%) had focal chronic pancreatitis. Eight
patients (13%) had an intermediate form with characteristics of both. Pancreatic adenocarcinoma
occurred in 227 patients (36%). The presence of pancreatitis without a discrete mass on endoscopic
ultrasonography (EUS) seemed to have clinical relevance with a positive likelihood ratio of 5.1. Mortality
after resection was nil in both groups.
Conclusion: The incidence of pancreatitis is 9.9% for patients scheduled to undergo a pancre-
atoduodenectomy. Of these patients, 38% had LPSP, 13% had a intermediate form and 49% had focal
chronic pancreatitis. The determination of the exact nature of a pancreatic head mass remains difficult.
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Introduction
Pancreatic adenocarcinoma (PCA) is the 4th leading cause of
death from cancer in the western world and complete resection by
pancreatoduodenectomy (PD) is the only potential curative treat-
ment.1,2 Although mortality has decreased significantly through-
out the last decade post-operative morbidity remains substantial.3
In contrast, chronic pancreatitis is generally treated conservatively
and surgery is only indicated when the quality of life is compro-
mised by major pain symptoms or deterioration of the nutritional
status, when adjacent organs, most commonly the duodenum, are
compressed by an inflammatory mass and when the clinician is
unable to determine the exact nature of the lesion. The treatment
of choice is a duodenum-preserving pancreatic head resection or
PD.
Despite improvements in radiological imaging modalities,
some patients will still undergo PD with a presumptive diagnosis
of PCA only to be found to have pancreatitis on final pathologic
review.4–8 In 1961, Sarles et al. was the first to describe a condition
called primary inflammatory sclerosis of the pancreas also known
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as ‘autoimmune sclerosing pancreatitis’ or simply ‘autoimmune
pancreatitis’.9 Nowadays this condition is commonly know as
lymphoplasmacytic sclerosing pancreatitis (LPSP).10–12 The
disease is characterized histologically by diffuse lymfoplasmacytic
infiltrate centred around pancreatic ducts and ductules, accom-
panied by obliterative phlebitis, acinar athrophy and interstitial
fibrosis.5,9,11,13–17 Another commonly found benign disease is
chronic focal pancreatitis characterized by duct dilation, fibrosis,
calcifications, fat necrosis and pseudocyst formation. This is often
associated with gallstone pancreatitis, pancreas divisum and
excessive alcohol ingestion.
The purpose of the present study was to determine the inci-
dence of pancreatitis and specifically the incidence of chronic
focal pancreatitis and lymphoplasmacytic sclerosing pancreatitis
in patients who underwent PD for suspected pancreatic adeno-
carcinoma and to analyse the presenting signs and symptoms and
findings during diagnostic work-up.
Patients and methods
From January 1992 to December 2005, 639 consecutive patients
underwent a pancreatoduodenectomy in the Academic Medical
Center in Amsterdam, the Netherlands. For analysis, all patients
with pancreatitis and pancreatic adenocarcinoma (PCA) who
underwent a pancreatoduodenectomy were selected from the pro-
spective database.
A standardized staging protocol was used which consists of an
orienting transabdominal ultrasonography (US) followed by a
helical computed tomography (CT) according to a dedicated pro-
tocol of the pancreas and liver.18,19 If a tumour was suspected but
could not be visualized by CT, an endoscopic ultrasonography
(EUS) or magnetic resonance imaging (MRI)/magnetic resonance
cholangiopancreatography (MRCP) was performed. In the Neth-
erlands, most patients undergo endoscopic retrograde cholangio-
pancreatography (ERCP) with placement of an endoprosthesis
for alleviation of jaundice, although this remains controversial.20
Tumour location and size, local ingrowth, lymphadenopathy and
distant metastases were all determined. All findings were analysed
by experienced radiologists and subsequently presented in a mul-
tidisciplinary team which also included gastroenterologists and
surgeons. Finally, the most likely diagnosis was registered in the
patient’s chart.
Pancreatoduodenectomy was defined as en bloc resection of the
duodenum and pancreatic head and distal bile duct and preferably
with preservation of the pylorus.21 Reconstruction was performed
by a retrocolic jejunal loop with an end-to-side pancreaticojejun-
ostomy, hepaticojejunostomy and finally an antecolic gastrojejun-
ostomy or duodenojejunostomy.
All complications were registered during hospital stay or read-
mission within 90 days after discharge. Complications were
divided into surgical complications (intra-abdominal abscess,
wound infection, haemorrhage, pancreatic leakage, biliary leakage
and delayed gastric emptying) and general post-operative compli-
cations (urological, pulmonary and cardiac).
All pathological records of patients with pancreatitis were
reevaluated by a senior pathologist (FJWTK) according to the
criteria described by various authors.5,9,11,13–17 Both entities had
histological signs of fibrosis. The criteria specific for LPSP were
the presence of periductalar inflammation, obliterative phlebitis
and acinar atrophy. The criteria for chronic focal pancreatitis were
the presence of duct dilation, calcifications, fat necrosis and
pseudocysts. The resection specimens were scored as either lym-
phoplasmacytic sclerosing pancreatitis (LPSP), chronic focal pan-
creatitis and an intermediate form if characteristics where present
specific to both forms. In the present study, IgG4 levels were not
measured as it is only recently been found that high IgG4 levels
correlate with LPSP, particularly in oriental patients.22
Data analyses were performed using SPSS® software (SPSS Inc.,
Chicago, IL, USA). A P-value of less than 0.05 was considered
statistically significant. The Kruskal–Wallis and Pearson’s c2-test
were performed where appropriate to analyse differences between
the three groups of patients with pancreatitis. The Student’s t-test,
Mann–Whitney, c2 test and Fisher’s exact test where used to
compare PCA and pancreatitis. Because the different diagnostic
procedures were not performed in all patients (e.g. EUS in 39% of
the patients), it was not seen fit to perform a formal multivariate
analysis. Instead the likelihood ratio and the 95% confidence
interval were calculated of all the significant data in order to
evaluate the impact on the likelihood of disease. The generally
accepted values were used to quantify the significance of the like-
lihood ratio (LR) was used and was defined as ‘large’ for LR+ of
>10 or LR- <0.1, ‘moderate’ for LR+ 5–10 or LR- 0.1–0.2, ‘small’
for LR+ 2–5 and LR- of 0.2–0.5, ‘minimal’ for LR+ of <2 and LR-
of >0.5 and ‘no effect’ for LR = 1.
Results
During the study period, 639 pancreatoduodenectomies were per-
formed. Of these, 63 patients (9.9%) eventually had pancreatitis
after histopathological examination. Of the 63 patients only 8
(1%) underwent surgery with the pre-operative diagnosis of
having pancreatitis. After pathological reexamination, 24 patients
(38%) had characteristics of LPSP, 31 patients (49%) of focal
chronic pancreatitis and 8 patients (13%) had an intermediate
form which could neither be described as a pure LPSP nor pure
focal chronic pancreatitis.
The general characteristics of the patients with pancreatitis are
summarized in Table 1. There were some differences within
the groups including significantly more patients with diabetes
mellitus in the LPSP group. Also, patients with LPSP tended to
smoke significantlymore often. Jaundice occurred significantly less
often in patients with focal chronic pancreatitis and consequently
the patients were less likely to be jaundiced during surgery and
underwent less pre-operative biliary drainage procedures.
The signs and symptoms and diagnostic work-up are sum-
marized in Table 2. Overall, patients with pancreatitis had a
significantly higher male-to-female ratio and were significantly
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Table 1 General characteristics of patients with pancreatitis
LPSP
n = 24
Intermediate
n = 8
Focal chronic
pancreatitis
n = 31
P
Gender male–female ratio 3.0 1.0 2.1 0.419
Mean age (SD) 57 (16) 52 (12) 58 (11) 0.537
Diabetes mellitus 7 (29%) 1 (13%) 1 (4%) 0.024
Smokers 20 (85%) 3 (38%) 13 (42%) 0.004
Alcohol use (2 units a day) 13 (55%) 3 (38%) 17 (55%) 0.665
Alcohol use (>2 units a day) 3 (13%) 1 (13%) 5 (16%) 0.919
Median duration of symptoms (range) 12 (2–100) 16 (8–100) 13 (0–260) 0.662
Pain 14 (58%) 5 (63%) 26 (84%) 0.086
Jaundice 23 (96%) 7 (88%) 16 (52%) 0.001
Weight loss reported by patients 15 (63%) 6 (75%) 23 (74%) 0.608
Mean BMI 24 (3.0) 22 (3.5) 23 (3.5) 0.359
Jaundice at surgery 9 (38%) 1 (13%) 1 (3%) 0.004
Preoperative biliary drainage 22 (92%) 4 (50%) 14 (45%) 0.001
Kruskal–Wallis and Pearson's c2-test were appropriate. LPSP, lymphoplasmacytic sclerosing pancreatitis.
Table 2 Characteristics, signs and diagnostic work-up comparing patients with pancreatitis with pancreatic adenocarcinoma
Pancreatitis
n = 63
PCA
n = 227
P
Gender male/female ratio 2.15 0.96 0.006
Mean age (SD) 57 (13) 66 (9) <0.001
Median duration of symptoms in weeks (range) 13 (0–260) 12 (0–104) 0.053
Pain 45 (71%) 102 (45%) <0.001
Jaundice
US performed n = 54 n = 198
Neoplasm seen 32 (59%) 148 (75%) 0.026
Size of neoplasm 3.0 (0.6–8.0) 2.7 (0.3–7.0) 0.014
ERCP performed n = 59 n = 220
Double duct sign 20 (34%) 95 (42%) 0.198
Suspicious brush 3 / 16 36 / 42 <0.001
CT available for analysis n = 56 n = 178
No discrete mass 26 (46%) 53 (28%) 0.022
Size of neoplasm 2.6 (1.5–5.5) 2.5 (1.0–7.0) 0.514
Head focally enlarged 24 (43%) 118 (67%) 0.002
Diffusely enlarged 6 (11%) 5 (3%) 0.025
Both ducts normal caliber 39 (70%) 58 (33%) <0.001
Pancreatic duct dilatation 4 (7%) 51 (29%) 0.001
CBD dilatation 5 (9%) 19 (10%) 0.707
Double duct sign 7 (13%) 50 (26%) 0.018
EUS performed n = 31 n = 78
Discrete mass 24 (77%) 56 (72%) 0.549
Signs of pancreatitis 6 (19%) 3 (4%) 0.015
Analysis comprised Mann–Whitney, c2 test and Fisher's exact test were applicable. US, ultrasonography; ERCP, endoscopic retrograde cholangio-
pancreatography; CT, computed tomography; CBD, common bile duct; EUS, endoscopic ultrasonography.
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younger. Patients with pancreatitis complained significantly more
of pain as first presenting symptom. Ultrasound was less likely to
find a discrete mass in the patients with pancreatitis. If a mass was
found it was significantly larger than in patients with PCA. An
ERCP with brush cytology was performed selectively as part of a
study in the early years and found that brush cytology was signifi-
cantly more suspicious for adenocarcinoma in the PCA group. In
28% of the patients with PCA there was no discrete mass seen on
CT. This was 46% in the pancreatitis group and was significantly
higher. In contrast, a diffusely enlarged pathological pancreatic
head was seen in 67% of the patients with pancreatic cancer
compared with 43% of the patients with pancreatitis. A EUS
found a discrete pancreatic mass in approximately three-quarters
of both groups but was able to detect signs of pancreatitis signifi-
cantly more often in patients with pancreatitis compared with
PCA (19% vs. 4%). Agreement concerning vascular involvement
between CT and EUS was 53 out of 68 patient (78%). Using CT,
seven patients who were resectable on EUS were found to be
unresectable while EUS found eight patients with vascular
ingrowth with no signs of ingrowth on CT.Agreement concerning
pathological lymph nodes was seen in 53 out of 59 patients (89%).
There were five patients with pathological nodes not found on
EUS and one patient had pathological nodes not seen on CT.
Tumours were significantly smaller on CT compared with EUS
(1 cm  1.5 vs. 2.3 cm  1.5, P < 0.05).
Several significant differences were seen with pre-operative
work-up and the likelihood ratios were calculated for all signifi-
cant variables and are shown in Table 3. Of all the variables only
signs of pancreatitis on EUS without a discrete mass was consid-
ered clinically relevant with a moderate impact on the positive
likelihood ratio and a large impact on the negative likelihood
ratio.
A separate analyses was made of patients with or without a
discrete mass on CT scan and the results are summarized in
Table 4. Differences, including a focally enlarged pancreatic head
were seen more often. A normal caliber of the ducts occurred in
49% of the patients with no mass on CT compared with 36% of
the patients with a mass. The other patients had dilatated ducts.
The EUS had similar outcome independent on the presence of a
mass on CT.
The short-term outcome is summarized in Table 5 and
comparable for both groups. The overall complication rate
defined as the occurrence of one or more complications was
seen in 133 patient (46%). Mortality was not seen in 290
pancreatoduodenectomies.
Discussion
In the present study, we found that the incidence of benign
inflammatory disease of the pancreas was 63 out 639 patients
(9.9%) who were scheduled to undergo pancreatoduodenectomy
for suspected pancreatic cancer. There were 24 patients (38%)
with LPSP, 8 patients (13%) with the intermediate form and 31
patients (49%) with focal chronic pancreatitis. A multitude of
symptoms and diagnostic factors were significantly different
between patients with pancreatitis and patients with pancreas
adenocarcinoma but only pancreatitis seen on EUS without a
discrete mass seemed to have any clinical relevance.
The incidence of pancreatitis in the present study is comparable
with that of the literature which suggest that benign pathology
Table 3 Value of various findings in predicting the presence of pancreatitis in patients scheduled for pancreatoduodenectomy
Variable LR+ 95% CI Impact on
Likelihood
LR- 95% CI Impact on
Likelihood
Gender 1.6 1.0–2.6 minimal 0.7 0.5–1.0 minimal
Age (median; <65) 2.0 1.2–3.4 small 0.6 0.5–0.9 minimal
Pain 1.9 1.2–3.2 minimal 0.6 0.5–0.9 minimal
Neoplasm seen on US 1.3 1.0–1.7 minimal 0.6 0.4–1.1 minimal
Brush during ERCP 4.6 1.7–13.3 small 0.2 0.08–0.5 moderate
No mass on CT 1.5 1.2–2.5 minimal 0.6 0.2–0.7 minimal
Head focally enlarged on CT 1.5 1.1–2.3 minimal 0.6 0.4–0.9 minimal
Diffusely enlarged pancreas on CT 1.1 1.0–1.3 minimal 0.3 0.09–1.2 small
Both ducts normal on CT 2.2 1.5–4.4 small 0.5 0.3–0.7 small
Pancreatic duct dilatation on CT 4.0 1.4–12 small 0.8 0.7–0.9 minimal
Double duct on CT 2.5 0.9–5.8 small 0.8 0.7–1.0 minimal
Signs of pancreatitis on EUS without discrete mass 5.1 2.5–12 moderate 0.05 0.02–0.2 large
LR+ positive likelihood ratio; LR- negative likelihood ratio; 95% CI: 95% confidence interval. Theoretical example pancreatitis occurs in 11% of all
scheduled pancreatoduodenectomies. However, in 22% it remains difficult to differentiate pancreatic adenocarcinoma from pancreatitis. This
prevalence leads to pretest odds of 1:5. In the case of negative brush during ERCP the post-test odds is 0.2*1:5 = 0.04. This leads to a post-test risk
of pancreatitis in 4% of these patients.
Impact on likelihood was defined as large for LR+ of >10 or LR- <0.1, moderate for LR+ 5–10 or LR- 0.1–0.2, small for LR+ 2–5 and LR- of 0.2–0.5,
minimal for LR+ of <2 and LR- of >0.5 and no effect for LR = 1.
US, ultrasonography; ERCP, endoscopic retrograde cholangio-pancreatography; CT, computed tomography; EUS. endoscopic ultrasonography.
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will be encountered in 3–12% of the pancreatoduodenectomies
done for a presumed malignancy.4,5,7,8,23,24 In a large study from the
Hopkins group and Mayo clinic the incidence was (176 out of
1574 scheduled pancreatoduodenectomies) 11.2%.12 However, the
proportion of patients with LPSP was lower (37 out of 176
patients), 21% compared with 38%, in the present study using the
same criteria.
In the present study, the mean age of patients with pancreatitis
was significantly lower compared with findings in the litera-
ture.12,25 The present study did find a female-to-male ratio consis-
tent with the literature.12,25 The clinical presentation of patients
with pancreatitis and pancreatic adenocarcinoma was very
similar. However, patients with pancreatitis presented more often
with pain and less often with jaundice. Patients with LPSP had the
Table 4 Discrete mass vs. no mass on CT
Discrete mass
n = 155
No discrete mass
n = 79
P
Head focally enlarged 133 (86%) 9 (11%) <0.001
Diffusely enlarged 3 (2%) 4 (5%) 0.230
Both ducts normal caliber 55 (36%) 39 (49%) 0.041
Pancreatic duct dilatation 47 (30%) 7 (9%) <0.001
CBD dilatation 12 (8%) 12 (15%) 0.076
Double duct sign 36 (23%) 19 (24%) 0.888
Gallbladder inflammation 4 (3%) 3 (4%) 0.691
ERCP performed n = 142 n = 76
Double duct sign 59 (42%) 27 (36%) 0.386
Suspicious brush 9 / 26 (35%) 7 / 22 (32%) 0.838
EUS performed n = 37 n = 48
Discrete mass 27 (73%) 37 (77%) 0.663
Signs of pancreatitis 4 (11%) 5 (10%) 1.000
Normal pancreas 6 (16%) 7 (15%) 0.836
Pancreatitis 26 (17%) 30 (38%) <0.001
Pancreatic cancer 129 (83%) 49 (62%) <0.001
Size of neoplasm 3.0 (1.5–11) 2.5 (1.0–5.0) 0.003
Analysis comprised Mann–Whitney, c2 test and Fisher's exact test were applicable.
CT, computed tomography; EUS. endoscopic ultrasonography.
Table 5 Intra-operative and post-operative characteristics
Pancreatitis
n = 63
PCA
n = 227
P
Median operative time 295 (180–552) 285 (140–62) 0.312
Vascular wedge resection 3 (5%) 38 (17%) 0.016
Estimated blood loss 1000 (200–3600) 1100 (50–8500) 0.731
Transfusion (no. of packed cells) 0 (0–29) 0 (0–14) 0.972
Overall post-operative complications 26 (41%) 107 (47%) 0.408
Pancreaticojejunostomy leakage 8 (13%) 14 (6%) 0.105
Hepaticojejunostomy leakage 1 (2%) 4 (2%) 1.000
Bleeding 6 (10%) 11 (5%) 0.220
Abscess 6 (10%) 19 (8%) 0.773
Wound infection 7 (11%) 14 (6%) 0.179
Delayed gastric emptying 12 (19%) 39 (17%) 0.731
Systemic 13 (21%) 59 (26%) 0.384
Relaparotomy 9 (14%) 19 (8%) 0.160
Post-operative hospital stay in days 14 (6–94) 14 (6–222) 0.840
Mortality 0 0 –
Analysis comprised Mann–Whitney, c2 test and Fisher's exact test were applicable. PCA, pancreatic adenocarcinoma.
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highest rate of jaundice comparable to that of the Hopkins and
Mayo experience. Intermittent jaundice which disappears sponta-
neously has been reported in patients with LPSP although not
noted in the patients from the present study.11
Significantly fewer patients with pancreatitis had a discrete
mass on CT scan. This was also seen in the Hopkins and Mayo
study.12 A CT scan generally describes diffuse enlargement of the
gland with loss of parenchymal markings.16,26 The entire pancre-
atic gland was described as diffusely enlarged in 11% of the
patients with delayed and prolonged enhancement of the affected
area.16,26 Diffuse enlargement was noted in 68% of the patients in
a Japanese study25 and in less than half in a Belgium study.27
The CT data in the present study has to be interpreted with
caution because the methodology of the CT scan has evolved
throughout the years. Slide thickness, the use of intravenous con-
trast and timing varied throughout the study period. The other
studies concerning this subject were subject to similar limitations.
Rather than relying on a single imaging modality, the diagnosis
of benign inflammatory disease of the pancreas is probably best
made by a panel of diagnostic studies. Other diagnostic modalities
such as ERCP with brush cytology, EUS and MRCP could aid in
making a correct diagnosis. For instance, a pancreaticogram gen-
erally shows fairly distinctive irregular narrowing of the small
ducts.16,28 Brush cytology was regularly performed in our centre
and very useful but lacked specificity.
A EUS seemed useful in the present study and should be per-
formed when in doubt. The absence or presence of signs of pan-
creatitis was discriminatory. A EUS can display small pancreatic
lesions undetectable by CT and MRI. In addition, EUS can also
localize lymph node metastases and/or vascular tumour infiltra-
tion with high sensitivity.29 The major limitations of the technique
are operator dependence and a limited field of visualization for
detecting metastatic spread to the liver and peritoneum. Also, the
positive predictive value of EUS for pancreatic cancer declines to
60% in patients with concurrent chronic pancreatitis.30 Histologi-
cal confirmation may be of additional value, but EUS-fine needle
aspiration (FNA) also showed some limitations in the presence of
chronic pancreatitis, in particular, a lower sensitivity in compari-
son to patients without chronic inflammation (73.8% vs. 91.3%,
P < 0.02).31
Finally, one might suggest that the addition of fluorodeoxyglu-
cose positron emission tomography (FDG-PET) might be useful
in distinguishing these entities.32 This novel tool was not readily
available during the study period.
Preoperative biopsies were rarely performed in the present
study and thus not analysed. An adequate sample is needed in
order to evaluate the tissue for all the pathological characteristics
of benign inflammatory disease. Even core biopsies will not
provide enough tissue to distinguish between these features. Fur-
thermore, there is a high rate of false-negative results from FNA
and biopsies as seen in a previous study, especially in patients
who have the smallest lesions and the best prognosis after
resection.33
Many studies have observed a marked clinical improvement of
patients with LPSP after steroid therapy.10,22,25,28,34–36 Considering
the fact that up to 10% of the patients undergo unnecessary lap-
arotomy, it is interesting to note a relatively straightforward trial
with steroids can prevent a laparotomy. This approach is only
warranted after accurate preoperative diagnosis which may be
possible with accurate imaging combined with the recently
described association of elevated IgG4 levels and LPSP.22,37 A non-
operative management strategy carries the risk of delaying the
treatment of pancreatic adenocarcinoma and strict criteria which
are diagnostic of LPSP are currently lacking. Steroids as a diag-
nostic tool are not useful in differentiating between LPSP from
PCA as a malignant pancreatic mass may also react to this treat-
ment and thus also decrease in size.
In the present study, morbidity was 46% and the mortality rate
was zero and this influenced the decision to perform a pancre-
atoduodenectomy. This combined with the fact that resection is
an excellent treatment for unmanageable pain in these patients. In
the present study, 71% of the patients had symptoms of pain.
Long-term follow-up suggests that patients who undergo a pan-
creatoduodenectomy for pancreatitis with unmanageable pain
have a successful outcome including a durable relief of symptoms
and an improved quality of life. This would in fact mean that
potentially only 18 patients (3%) out of 639 scheduled for a pan-
creatoduodenectomy undergo unnecessary surgery.
TheMemorial Sloan-Kettering group proposed an algorithm in
which IgG4 levels are obtained in patients with a suspected LPSP.24
If elevated, the patient is placed on a short trial with steroids
followed by a repeat CT scan in 4–6 weeks. If there is a decrease in
the size of the mass, steroids should be discontinued. If there is an
increase in size or no change the patient should undergo resection.
This algorithm does not take into account the fact that patients
with pancreatic cancer could possible also react to steroids as
many neoplasms are surrounded by a zone carcinoma induced
pancreatitis. However, IgG4 levels are not always elevated in Cau-
casian patients compared with oriental patients.22,37
The incidence of pancreatitis is 9.9% of all scheduled pancre-
atoduodenectomies. The differentiation is very challenging. An
EUS has some potential to discriminate but the results are still not
optimal. A clear-cut diagnostic tool is not readily available but
instead the combined result of many tests has to guide the clini-
cian in the decision-making process.
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